Abstract:Background Atrial fibrillation (AF) and heart failure (HF) are intertwined conditions with high mortality rates and large impact on quality of life, and their coexistence is increasingly prevalent. Both conditions influence each other's development and progression, and share many risk-factors—such as hypertension, obesity, diabetes mellitus and ischaemic heart disease. Moreover, their combined presence further increases the risk of hospitalization and mortality. The biological mechanisms at play in HF patients with AF may therefore differ from those in HF patients without AF. Purpose We aimed to describe the differences in pathophysiological pathways in HF patients with versus without AF, by identifying biomarkers associated with AF from a panel of 4210 circulating proteins and subsequently examining biological mechanisms related to these biomarkers. Methods We examined 377 ambulant HF patients with reduced ejection fraction from a longitudinal cohort study. We measured 4210 circulating proteins in baseline blood samples using an aptamer-based multiplex proteomic approach. Associations between AF (known AF history or AF on the baseline ECG) and the proteins were assessed using linear regression models adjusted for age, sex, kidney function and duration of HF at baseline. Associations of proteins significantly related to AF, with biological processes, were assessed using network-based clustering and subsequent enrichment analysis. Results The median [25th, 75th percentile] age was 64 [55, 72], 73% [274/377] were male, 28% [104/375] had NYHA-class III or IV, and 37% [139/377] had AF (either AF history: 36% [137/377] or AF on baseline ECG: 8% [30/374]). We found 71 proteins significantly associated with AF (FDR<0.05), including well-studied (e.g. troponin T, IGFBP7, MFAP4, BMP10, angiopoietin 2) and lesser studied (e.g. olfactomedin−like protein 3, keratocan, basigin) proteins in the AF domain. Our pathway analysis revealed clusters of proteins related to various underlying mechanisms, such as axon guidance, elastic fibre assembly, macrophage derived foam cell differentiation, ether lipid metabolism and amyloid-beta binding. Overviews of the significantly associated proteins and related biological mechanisms are provided in Figures 1 and 2. Conclusion HF patients with AF have distinct proteomic profiles and these differences are related to various biological mechanisms, many of which can be associated with atrial remodelling. This study provides an overview of the biological mechanisms behind AF in HF, confirms prior findings regarding AF-related proteins, and could guide future research in novel treatment targets and HF-AF management.Figure 1:Proteins associated with AFFigure 2:Biological mechanisms

Plasma proteomic analysis of association between atrial fibrillation, coronary microvascular disease and heart failure.

Proteomic profiles of patients with atrial fibrillation provide candidate biomarkers for diagnosis

Proteomic biomarkers and biological mechanisms associated with atrial fibrillation in heart failure patients

Proteomic and genomic evaluation of plasma protein biomarkers for atrial fibrillation

Protomic Profiles of Patients with Atrial Fibrillation Provide New Candidate Biomakers for Diagnosis

Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation.

Abstract 16835: Plasma Proteomics and Risk of Incident HFpEF and HFrEF: The Atherosclerosis Risk in Communities Study

A plasma proteomic approach in patients with heart failure after acute myocardial infarction: insights into the pathogenesis and progression of the disease

The plasma proteome is linked with left ventricular and left atrial function parameters in patients with chronic heart failure

Abstract 11983: Biomarker Profile of Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction or Reduced Ejection Fraction: Insights From the ARISTOTLE Trial

Plasma Olink Proteomics Reveals Novel Biomarkers for Prediction and Diagnosis in Dilated Cardiomyopathy with Heart Failure

Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in Communities [ARIC] Study)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum

Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development

Plasma Proteomic Insights for Identification of Novel Predictors and Potential Drug Targets in Atrial Fibrillation: A Prospective Cohort Study and Mendelian Randomization Analysis

Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling

Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study

Proteomic Analysis Of Atrial Appendages Revealed The Pathophysiological Changes Of Atrial Fibrillation

The Association of Protein Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction

Pericardial Fluid Annexin A1 Is a Marker of Atrial Fibrillation in Aortic Stenosis: A Proteomics Analysis

Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation